Identification of sars-cov-2 mpro inhibitors containing p1⠒ 4-fluorobenzothiazole moiety highly active against sars-cov-2

HIGHLIGHTS

• who: Nobuyo Higashi-Kuwata from the USA) (a549-hace2tpsa)and were cultured in growth medium in, ., u00b5g/ ml of Puromycin and , u00b5g/ml of Hygromycein. SARS-Co, strain JPN/TY/, (SARS-CoV- WK-521) was obtained from the National Institute of Infectious Diseases (Tokyo, Japan). Five clinically isolated SARS-Co, mutant strains were used in the current study: a B.1.1., (alpha) strain [hCoV-19/Japan/QHN001/, (SARS-CoV- QHN001, GISAID Accession ID have published the paper: Identification of SARS-CoV-2 Mpro inhibitors containing P1u2812 4-fluorobenzothiazole moiety highly active against SARS-CoV-2, in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.